Adjuvant therapy of stage II breast cancer |
| |
| Authors: | Charles A. Hubay M.D. Olof H. Pearson M.D. James S. Marshall M.D. Thomas A. Stellato M.D. Robert S. Rhodes M.D. Sara M. DeBanne Ph.D Judah Rosenblatt Ph.D. Edward G. Mansour M.D. Robert E. Hermann M.D. James C. Jones M.D. William J. Flynn M.D. Charles Eckert M.D. William L. McGuire M.D. Participating Investigators |
| |
| Affiliation: | (1) Department of Surgery, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA;(2) Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA;(3) Department of Biometry, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA;(4) Cleveland Metropolitan General Hospital, Cleveland, Ohio, USA;(5) Cleveland Clinic, Cleveland, Ohio, USA;(6) St. Luke's Hospital, Cleveland, Ohio, USA;(7) Youngstown Hospital Association, Youngstown, Ohio, USA;(8) Albany Medical Center, Albany, New York, USA;(9) University of Texas Health Science Center, San Antonio, Texas, USA;(10) Akron General Medical Center, Akron, Ohio, USA |
| |
| Abstract: | Summary A prospective, randomized clinical trial of adjuvant treatment of 318 stage II breast cancer patients, using chemotherapy, the antiestrogen tamoxifen, and immunotherapy is reported at 48 months follow-up.Women whose primary tumors have no estrogen receptors fall into a significantly poorer prognostic group than those whose tumors contain estrogen receptors. None of the adjuvant regimens appeared to offer any clear-cut advantage for the estrogen receptor negative patients.Those women whose primary tumor contains estrogen receptors appear to be in a prognostically favorable group, when their treatment regimen included the antiestrogen, tamoxifen. The adjuvant use of BCG immunotherapy does not appear to offer additional benefit, but the follow-up period of these treated patients is too brief to be conclusive.A longer period of observation is needed to determine whether this systemic treatment in estrogen receptor positive patients is preventing recurrence or merely delaying it.Address for reprints: C.A. Hubay, M.D., Dept. of Surgery, 2074 Abington Rd., Cleveland, OH 44106. |
| |
| Keywords: | estrogen receptor antiestrogen tamoxifen chemotherapy immunotherapy stage II breast cancer |
| 本文献已被 SpringerLink 等数据库收录！ |
|
